Previous studies demonstrated that SCFAs contributed to obesity and liver steatosis as they provide ~10% of daily caloric consumption and might enhance nutrient absorption by promoting the expression of glucagon-like peptide 2 (GLP-2), obesity, and liver steatosis that could trigger liver inflammation and NAFLD, as well as HF (31). The gene discussed is GCG; the disease is inflammation.